Target intelligence / Profile preview

Immunoglobulin G Fc gamma receptor (FcγR (or IgG FcγR))

Target
FcγR (or IgG FcγR)
Molecular classification
Receptor, Immunoglobulin superfamily, Non-catalytic tyrosine-phosphorylated receptor
01

Overview

Immunoglobulin G Fc gamma receptors (FcγRs) are a family of cell surface receptors that bind the Fc region of IgG antibodies, playing a critical role in linking humoral and cellular immunity[2][4][5]. FcγRs are classified into several types—including the high-affinity FcγRI (CD64), and the low-to-intermediate affinity FcγRII (CD32) and FcγRIII (CD16)—each with distinct affinities, cellular distribution, and signaling properties[2][7]. They mediate antibody-dependent functions such as phagocytosis, ADCC, degranulation, antigen presentation, and cytokine production, using immunoreceptor tyrosine-based activation or inhibition motifs (ITAM/ITIM) in their cytoplasmic domains or associated accessory chains[2][4][5]. Differential binding of IgG subclasses and polymorphic variants of FcγRs influences clinical responses to monoclonal antibody therapies and susceptibility to autoimmune or infectious diseases[6][7]. FcγRs are key therapeutic targets in immuno-oncology and autoimmunity, both as mediators of antibody efficacy and as direct drug targets in efforts to enhance or modulate immune cell function[1][3][6].

Other names
Fc gamma receptorIgG Fc receptorFcγ receptorCD64 (FcγRI)CD32 (FcγRII)CD16 (FcγRIII)
02

Mechanism of action

Engagement of Fc region of IgG antibodies leading to activation of effector immune cells. Initiation of phagocytosis via ITAM signaling. Triggering ADCC and degranulation in NK cells and other effector cells. Modulation of cytokine secretion and inflammatory mediator release.

03

Biological functions

Immune responseSignal transductionPhagocytosisAntibody-dependent cellular cytotoxicity (ADCC)Cytokine productionAntigen uptake and presentation
04

Disease associations

CancerAutoimmune diseaseInfectionInflammation
05

Safety considerations

Potential for excessive immune activation and cytokine release syndromeOff-target effects leading to tissue damage or autoimmunityVariability in therapeutic monoclonal antibody efficacy due to FcγR polymorphisms
06

Interacting drugs

Monoclonal antibodies (e.g., rituximab, trastuzumab, cetuximab, alemtuzumab)

2 more in the full profile.

07

Biomarkers

FcγR genotype or polymorphism (e.g., FcγRIIa H131R, FcγRIIIa V158F) for predicting response to antibody therapyFcγR expression levels on immune cell subsets

Beyond the preview

Go deeper on Immunoglobulin G Fc gamma receptor (FcγR (or IgG FcγR)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin G Fc gamma receptor (FcγR (or IgG FcγR)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call